**Supplemental Table 1.** A comparison of patient and liver injury characteristics in patients with suspected drug-induced liver injury (DILI). Data are shown for the whole study cohort and compared between patients adjudicated as having a non-DILI liver injury and those adjudicated as having DILI.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable**  | **All patients****N=551** | **Possible or unlikely DILI** **( n=109)** | **Probable, very likely or definite DILI** **( n=442)** | **P value** |
| Age (years) | 50 ± 18 | 53 ± 18.5 | 49 ± 17.8 | 0.04 |
| Male (%) | 45.6 | 52.3 | 43.9 | 0.11 |
| Body mass index (kg/m2)  | 28.2 ± 7.1 | 28 ± 6.9 | 28.2 ± 7.1 | 0.9 |
| Race/ethnicity (%)WhiteBlackAsianOther | 79.613.32.54.7 | 76.914.81.96.5 | 80.312.92.74.41 | 0.6 |
| Hispanics (%) | 5.6 | 6.4 | 5.4 | 0.7 |
| Latency (days)  | 163 ± 496 | 173 ± 493 | 160 ± 497 | 0.8 |
| Alanine aminotransferase (IU/L)  | 725 ± 921 | 739 ± 1117 | 721 ± 867 | 0.3 |
| Alkaline Phosphatase (IU/L)  | 286 ± 280 | 365 ± 469 | 267 ± 2.4 | 0.08 |
| Bilirubin (mg/dL)  | 6.3 ± 5.8 | 6.1 ± 6.4 | 6.3 ± 5.7 | 0.3 |
| INR (at onset)INR (at peak MELD) | 1.3 ± 0.81.7 ± 1.5 | 1.5 ± 0.82.1 ± 2.1 | 1.3 ± 0.81.6 ± 1.3 | <0.001<0.001 |
| Creatinine (mg/dL)  | 1.2 ± 0.5 | 1.3 ± 0.7 | 1.2 ± 0.5 | 0.8 |
| MELD  | 15.1 ± 6.4 | 16.2 ± 7.9 | 14.8 ± 6.1 | 0.2 |
| Albumin (g/dL)  | 3.5 ± 0.7 | 3.3 ± 0.8 | 3.6 ± 0.7 | 0.006 |
| R value  | 11.2 ± 16.9 | 10.8 ± 19.5 | 11.3 ± 16.4 | 0.06 |
| Injury pattern (%)HepatocellularMixedCholestatic | 48.622.528.9 | 46.812.840.4 | 49.124.926 | 0.003 |
| Class of agents (most common) (%)AntimicrobialAntineoplastic CardiovascularHerbal and dietary supplementNeurologic | 45.26.29.316.57.4 | 451.815.613.89.2 | 46.67.27.717.27 | 0.960.0360.010.40.4 |
| Number of implicated agents | 1.4±0.7 | 1.4±0.7 | 1.4±0.7 | 0.5 |
| Number of concomitant drugs | 7.8±7.5 | 9.3±8.9 | 7.4±7.1 | 0.019 |
| RUCAM score | 6.2±2.3 | 4.3±2.8 | 6.7±1.8 | <0.001 |

¶Values shown as mean ± standard deviation, or percentages.

**Abbreviations: CCI**, Charlson Comorbidity Index; **DILI**, drug-induced liver injury; **INR**, international normalized ratio; **MELD,** Model for End-stage Liver Disease; **RUCAM,** Roussel Uclaf Causality Assessment Method.